Barcelona, 06 September 2021 CTH120, designed using artificial intelligence techniques, will start Phase I in 2022 CTH120 designation as orphan drug validates and empowers Connecta Therapeutics's strategy in neurodevelopmental diseases CTH120 Connecta Therapeutics has received approval as orphan drug from the European Medicines Agency (EMA) to treat fragile...
Continue readingBarcelona The public-private consortium has obtained a grant of €1.97 million from the Spanish National Innovation Agency Preclinical studies have shown that the CTH120 molecule can modulate neuroplasticity, the ability of cells of the nervous system to regenerate in response to pathological influences The public-private consortium formed by...
Continue readingBarcelona The public-private consortium has earned this grant through the 2019 “Collaboration Challenges” programme The public-private consortium formed by the biotech company Connecta Therapeutics, the Centre for Genomic Regulation (CRG) and the Hospital del Mar Medical Research Institute (IMIM) has received a grant for 1,970,520 Euro from...
Continue readingBarcelona Inveready led the round of investment. CDTI and the biotechnology company’s founders also participated. Connecta Therapeutics was founded in Barcelona in 2019 as a spin-off of Prous Institute for Biomedical Research to develop new therapies for the central nervous system. Fragile X syndrome is an inherited genetic...
Continue reading